Tag: Eli Lilly
Lilly’s oral GLP-1 orforglipron tops Phase 3 trials in type 2...
In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint
Eli Lilly expands operations in India, to invest $1 Billion for...
Investment to expand manufacturing and global medicine supply capacity — resonating with the Make in India agenda
Lilly’s oral GLP-1 Orforglipron clears third Phase 3 trial, set for...
Participants with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost an average of 10.4 kg (10.5%) on the highest dose, with A1C reduced by an average of 1.8%
Lilly expands India presence with inauguration of Hyderabad site to accelerate...
Hyderabad site will support innovation and strengthen digital capabilities across Lilly’s global operationsHyderabad site will support innovation and strengthen digital capabilities across Lilly’s global operations
Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction & a safety...
Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year
Post CDSCO approval, Lilly launches Mounjaro, a first of its kind...
The drug delivers superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials
Eli Lilly appoints Winselow Tucker as its President & GM
In a related move, Vineet Gupta, Associate VP, Managing Director, India, will transition to a new leadership role in Lilly’s headquarters in Indianapolis, USA
Eli Lilly to establish new global capability centre in Hyderabad, hire...
New centre expected to open in mid-2025 will drive innovation and technological advancement
Lupin acquires Huminsulin from Lilly to enhance Diabetes portfolio
The Huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and children
Lilly’s GBP279 million investment set to boost UK life sciences sector
As per GlobalData, the initiative is set to accelerate early-stage ventures and spearhead advancements in obesity treatments, invigorating the UK life sciences sector